Skip to main content
OpenTrials
Completed

NCT Number: NCT03946072

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neurocognitive Dysfunction Cognition Disorders Mental Disorders Neurocognitive Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada

Loading trial locations.

About this study

This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs). Participants will be followed for 6 months post-study procedure. This study will be conducted at up to 12 clinical sites in the United States. A total of one-hundred and fifty (150) participants will be enrolled and randomized.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • Planned/scheduled endocardial ventricular tachycardia (VT) or premature ventricular contraction (PVC) catheter ablation procedure
  • For this patient, the current plan of the operator must be to pursue a catheter ablation target in the left ventricular endocardium that can be accessed by either a transseptal puncture or retrograde aortic approach
  • Life expectancy of at least 1 year
  • Willing and able to undergo pre- and post-ablation MRIs
  • Willing and able to return and comply with scheduled follow up visits (through the 6 month follow-up)
  • Willing and able to provide written informed consent

Exclusion criteria

  • Planned epicardial ablation that would include a coronary angiogram (during the index ventricular tachycardia (VT) or premature ventricular contraction (PVC) catheter ablation procedure)
  • Any contraindication to MRI (as defined by the institution performing the MRI)
  • Clinical contraindication to a retrograde aortic approach as determined by the treating physician, including:
  • Severe aortic stenosis
  • Mechanical aortic valve
  • Clinical contraindication to a transseptal puncture as determined by the treating physician, including:
  • Severe Mitral valve stenosis
  • Mechanical Mitral valve
  • Atrial septal defect (ASD) or Patent foramen ovale (PFO) closure device that would preclude a transseptal puncture
  • Mitraclip or Alfieri mitral valve repair that would preclude a transseptal puncture
  • Planned or known need to perform either a retrograde aortic approach or transseptal approach (such as to target another site during the same procedure)
  • Inability to speak, read, and write in the English language at a 6th grade level (required for the Neurocognitive Function Testing)
  • Current mental impairment or other diagnosis which precludes accurate assessment of neurocognitive function or which may not allow patient to understand the nature, significance and scope of the study
  • Inability to perform neurocognitive function testing after > 24 hours free of sedating medications

Treatment and study plan

Transseptal Aortic Approach Catheter Ablation Procedure

Procedure

The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.

Retrograde Aortic Approach Catheter Ablation Procedure

Procedure

The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.

Primary outcomes

  1. cerebral embolic lesion incidence

    Time frame: on day 1 post-ablation

    incidence of new cerebral embolic lesions measured by magnetic resonance imaging (MRI) post-ablation as compared to pre-ablation imaging studies

  2. overall neurocognitive function, change

    Time frame: from baseline (pre-ablation) to 6 months post-ablation

    percent change in overall neurocognitive function score from baseline (pre-ablation). The neurocognitive function examination includes items from the Brain Health Assessment, a validated, multi-domain testing battery aims to detect cognitive impairment in older adults. The TRAVERSE Testing Battery will include the following tests: Favorites (Forms A and B), Match (Forms A and B), Favorites Delay (Forms A and B), Favorites Recognition (Forms A and B), Dot Counting (Forms A and B), Flanker, and Running Dots.

Secondary outcomes

  1. new cerebral embolic lesions, number

    Time frame: on day 1 post-ablation

    number of new cerebral embolic lesions per person, measured by magnetic resonance imaging (MRI) post-ablation as compared to pre-ablation imaging studies

  2. complications related to the ablation procedure, rate

    Time frame: post-ablation, through Month 6

    rate of complications related to the ablation procedure

  3. symptoms specific to VT/PVC, change

    Time frame: from pre-ablation to post-ablation, through Month 6

    change in self-reported symptoms specific to VT/PVC

  4. quality of life composite score, change

    Time frame: from baseline (pre-ablation) to 6 months post-ablation

    change in quality of life score (composite summary points) measured using the Short Form 12-item Survey (SF-12), a validated measure of health status.

  5. physical activity (MET-min/week), change

    Time frame: from baseline (pre-ablation) to 6 months post-ablation

    change in total physical activity (MET-min/week) measured using the International Physical Activity Questionnaire (IPAQ) short format questionnaire, validated for physical activity-related energy expenditure.

  6. recurrent arrhythmias, rate

    Time frame: at 6 months post-ablation

    rate of recurrent arrhythmias determined as part of routine clinical care, measured using ECG and continuous ECG monitoring, if data is available

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

Multi-center Comparative Effectiveness Randomized Trial to Assess a Transseptal Approach to Left Ventricular Ablation Compared to Retrograde to Prevent Cerebral Emboli & Neurocognitive Decline in Adults With Ventricular Tachycardia/Premature Ventricular Contractions

Acronym: TRAVERSE

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
May 10, 2019
Registry last updated
Dec 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.